BACKGROUND: The incidence, survival, and prevalence of neuroendocrine tumors (NETs) in children were determined as a first step in improving diagnosis and therapy. Outcomes were compared with neuroblastoma, a pediatric malignancy that shares several biomarkers. METHODS: Incidence rates, observed survival rates and 31-year limited duration prevalence counts were obtained from SEER*Stat for diagnosis years 1975 to 2006. These rates were compared between and within NETs and neuroblastoma for demographic and tumor-related variables from nine standard SEER registries for ages 0-29 years. Multivariate Cox regression was performed to identify prognostic factors for survival in NETs. RESULTS: The number of NETs was 1,073 compared to 1,664 neuroblastomas. The most common NET sites were lung, breast, and appendix. NET 5-year observed survival rates increased from 83% between 1975 and 1979 to 84% for the 2000-2006 period, while analogous neuroblastoma survival rates steadily increased from 45-73%. Five-year observed survival was less than 30% in females with NETs of the cervix and ovary. The estimated 31-year limited duration prevalence for NETs as of January 1, 2006 in the U.S. population was 7,724 compared to 9,960 for neuroblastomas. Age-adjusted multivariate Cox Regression demonstrated small cell histology, primary location in the breast, and distant stage as major predictors of decreased survival. CONCLUSIONS: While survivorship has significantly increased for neuroblastoma, those diagnosed with NETs have shown no increase in survival during this 31-year period. NETs constitute an unrecognized cancer threat to children and young adults comparable to neuroblastoma in both number of affected persons and disease severity.
BACKGROUND: The incidence, survival, and prevalence of neuroendocrine tumors (NETs) in children were determined as a first step in improving diagnosis and therapy. Outcomes were compared with neuroblastoma, a pediatric malignancy that shares several biomarkers. METHODS: Incidence rates, observed survival rates and 31-year limited duration prevalence counts were obtained from SEER*Stat for diagnosis years 1975 to 2006. These rates were compared between and within NETs and neuroblastoma for demographic and tumor-related variables from nine standard SEER registries for ages 0-29 years. Multivariate Cox regression was performed to identify prognostic factors for survival in NETs. RESULTS: The number of NETs was 1,073 compared to 1,664 neuroblastomas. The most common NET sites were lung, breast, and appendix. NET 5-year observed survival rates increased from 83% between 1975 and 1979 to 84% for the 2000-2006 period, while analogous neuroblastoma survival rates steadily increased from 45-73%. Five-year observed survival was less than 30% in females with NETs of the cervix and ovary. The estimated 31-year limited duration prevalence for NETs as of January 1, 2006 in the U.S. population was 7,724 compared to 9,960 for neuroblastomas. Age-adjusted multivariate Cox Regression demonstrated small cell histology, primary location in the breast, and distant stage as major predictors of decreased survival. CONCLUSIONS: While survivorship has significantly increased for neuroblastoma, those diagnosed with NETs have shown no increase in survival during this 31-year period. NETs constitute an unrecognized cancer threat to children and young adults comparable to neuroblastoma in both number of affected persons and disease severity.
Authors: Aaron I Vinik; Maria P Silva; Eugene A Woltering; Gene Woltering; Vay Liang W Go; Richard Warner; Martyn Caplin Journal: Pancreas Date: 2009-11 Impact factor: 3.327
Authors: S L Spunt; C B Pratt; B N Rao; M Pritchard; J J Jenkins; D A Hill; A M Cain; A S Pappo Journal: J Pediatr Surg Date: 2000-09 Impact factor: 2.545
Authors: Amanda Townsend; Tim Price; Sue Yeend; Ken Pittman; Kevin Patterson; Colin Luke Journal: J Clin Gastroenterol Date: 2010-03 Impact factor: 3.062
Authors: Marcin Kałuzny; Marek Bolanowski; Małgorzata Sukiennik-Kujawa; Piotr Ponikowski; Daria Handkiewicz-Junak; Barbara Jarzab; Aleksandra Jawiarczyk; Joanna Syrycka Journal: Endokrynol Pol Date: 2009 Sep-Oct Impact factor: 1.582
Authors: Chenue Abongwa; Sarah Mott; Blanca Schafer; Parren McNeely; Ghada Abusin; Thomas O'Dorisio; Gideon Zamba; M Sue O'Dorisio; Yusuf Menda Journal: Am J Nucl Med Mol Imaging Date: 2017-11-01
Authors: Simone de Campos Vieira Abib; Chan Hon Chui; Sharon Cox; Abdelhafeez H Abdelhafeez; Israel Fernandez-Pineda; Ahmed Elgendy; Jonathan Karpelowsky; Pablo Lobos; Marc Wijnen; Jörg Fuchs; Andrea Hayes; Justin T Gerstle Journal: Ecancermedicalscience Date: 2022-02-17
Authors: Thomas A Hope; Lisa Bodei; Jennifer A Chan; Ghassan El-Haddad; Nicholas Fidelman; Pamela L Kunz; Josh Mailman; Yusuf Menda; David C Metz; Erik S Mittra; Daniel A Pryma; Diane L Reidy-Lagunes; Simron Singh; Jonathan R Strosberg Journal: J Nucl Med Date: 2020-02 Impact factor: 11.082
Authors: Lina Chernov; Rebecca J Deyell; Malathi Anantha; Nancy Dos Santos; Roger Gilabert-Oriol; Marcel B Bally Journal: Cancer Med Date: 2017-05-23 Impact factor: 4.452
Authors: Maria Alejandra Forero Molina; Elizabeth Garcia; Deyanira Gonzalez-Devia; Rafael García-Duperly; Alonso Vera Journal: World Allergy Organ J Date: 2017-09-04 Impact factor: 4.084